Research Article
Methylation of DLEC1 Promoter Is a Predictor for Recurrence in Chinese Patients with Gastric Cancer
Table 3
Multivariate analysis of recurrence-free survival in gastric cancer according to clinicopathological variables and DLEC1 methylation.
| Clinicopathological variables | HR | 95% CI | value |
| Age (≤65 versus >65) | 1.12 | 0.91–2.04 | 0.073 | Gender (male versus > female) | 1.05 | 0.70–1.21 | 0.103 | Tumor size (<4 versus ≥4) | 1.58 | 1.16–2.26 | 0.058 | Depth of invasion (Tis-1 versus T2-4) | 3.81 | 1.68–6.85 | 0.008 | Lymphatic invasion (+ versus −) | 4.54 | 2.06–7.36 | 0.001 | Venous invasion (+ versus −) | 2.86 | 1.43–5.01 | 0.017 | TNM staging (0-I versus II–IV) | 2.32 | 1.26–4.83 | 0.036 | Lauren classification (intestinal versus diffuse type) | 3.66 | 1.37–8.94 | 0.009 | Lymph node metastasis (+ versus −) | 3.92 | 1.78–7.15 | 0.002 | DLEC1 methylation (>35.10 versus ≤35.10) | 2.43 | 1.38–5.07 | 0.025 |
|
|